351 related articles for article (PubMed ID: 21994416)
1. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
[TBL] [Abstract][Full Text] [Related]
2. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
[TBL] [Abstract][Full Text] [Related]
3. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH
BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843
[TBL] [Abstract][Full Text] [Related]
4. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Saridaki Z; Weidhaas JB; Lenz HJ; Laurent-Puig P; Jacobs B; De Schutter J; De Roock W; Salzman DW; Zhang W; Yang D; Pilati C; Bouché O; Piessevaux H; Tejpar S
Clin Cancer Res; 2014 Sep; 20(17):4499-4510. PubMed ID: 25183481
[TBL] [Abstract][Full Text] [Related]
5. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
Langevin SM; Christensen BC
Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702
[TBL] [Abstract][Full Text] [Related]
6. A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer.
De Ruyck K; Duprez F; Ferdinande L; Mbah C; Rios-Velazquez E; Hoebers F; Praet M; Deron P; Bonte K; Speel EJ; Libbrecht L; De Neve W; Lambin P; Thierens H
Cancer Epidemiol; 2014 Oct; 38(5):591-8. PubMed ID: 25127693
[TBL] [Abstract][Full Text] [Related]
7. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
[TBL] [Abstract][Full Text] [Related]
9. KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter.
Ryan BM; Robles AI; Harris CC
Clin Cancer Res; 2012 Jun; 18(12):3487-8; author reply 3489. PubMed ID: 22669132
[No Abstract] [Full Text] [Related]
10. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.
Christensen BC; Moyer BJ; Avissar M; Ouellet LG; Plaza SL; McClean MD; Marsit CJ; Kelsey KT
Carcinogenesis; 2009 Jun; 30(6):1003-7. PubMed ID: 19380522
[TBL] [Abstract][Full Text] [Related]
11. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
[TBL] [Abstract][Full Text] [Related]
12. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
Ruzzo A; Graziano F; Vincenzi B; Canestrari E; Perrone G; Galluccio N; Catalano V; Loupakis F; Rabitti C; Santini D; Tonini G; Fiorentini G; Rossi D; Falcone A; Magnani M
Oncologist; 2012; 17(6):823-9. PubMed ID: 22584434
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F; Chau I; Cunningham D; Peckitt C; Lampis A; Hahne JC; Braconi C; Tabernero J; Glimelius B; Cervantes A; Begum R; Gonzalez De Castro D; Hulkki Wilson S; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Valeri N
Ann Oncol; 2015 Sep; 26(9):1936-1941. PubMed ID: 26162609
[TBL] [Abstract][Full Text] [Related]
14. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.
Pan XM; Sun RF; Li ZH; Guo XM; Zhang Z; Qin HJ; Xu GH; Gao LB
Tumour Biol; 2014 Jan; 35(1):831-5. PubMed ID: 23975373
[TBL] [Abstract][Full Text] [Related]
15. The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.
Ulusan M; Sen S; Yilmazer R; Dalay N; Demokan S
Pathol Res Pract; 2022 Nov; 239():154147. PubMed ID: 36228348
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer.
Huang CJ; Teng HW; Chien CC; Lin JK; Yang SH
PLoS One; 2014; 8(6):e65117. PubMed ID: 23755178
[TBL] [Abstract][Full Text] [Related]
17. Association analysis of miRNA-related genetic polymorphisms in miR-143/145 and KRAS with colorectal cancer susceptibility and survival.
Wang D; Liu Q; Ren Y; Zhang Y; Wang X; Liu B
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33825830
[TBL] [Abstract][Full Text] [Related]
18. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
[TBL] [Abstract][Full Text] [Related]
19. Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.
Kang M; Shen XJ; Kim S; Araujo-Perez F; Galanko JA; Martin CF; Sandler RS; Keku TO
Cancer Biomark; 2013; 13(5):359-66. PubMed ID: 24440976
[TBL] [Abstract][Full Text] [Related]
20. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.
Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ
Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]